Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.
- Published In:
- The New England journal of medicine, 393(18), 1796-1806 (2025)
- Authors:
- Wharton, Sean(7), Aronne, Louis J(7), Stefanski, Adam(8), Alfaris, Nasreen F, Ciudin, Andreea, Yokote, Koutaro, Halpern, Bruno, Shukla, Alpana P, Zhou, Chunmei, Macpherson, Lisa, Allen, Sheryl E, Ahmad, Nadia N, Klise, Suzanne R
- Database ID:
- RPEP-14142
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-14142APA
Wharton, Sean; Aronne, Louis J; Stefanski, Adam; Alfaris, Nasreen F; Ciudin, Andreea; Yokote, Koutaro; Halpern, Bruno; Shukla, Alpana P; Zhou, Chunmei; Macpherson, Lisa; Allen, Sheryl E; Ahmad, Nadia N; Klise, Suzanne R. (2025). Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.. The New England journal of medicine, 393(18), 1796-1806. https://doi.org/10.1056/NEJMoa2511774
MLA
Wharton, Sean, et al. "Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.." The New England journal of medicine, 2025. https://doi.org/10.1056/NEJMoa2511774
RethinkPeptides
RethinkPeptides Research Database. "Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist ..." RPEP-14142. Retrieved from https://rethinkpeptides.com/research/wharton-2025-orforglipron-an-oral-smallmolecule
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.